Steven Ades, M.D., M.Sc.
Professor of Medicine, Hematology and Oncology
Medical Director, University of Vermont Cancer Center Clinical Trials Office
Medical Oncologist, UVM Health Network
- M.D., McGill University
- M.Sc., Epidemiology, McGill University
- B.Sc., Chemistry, McGill University
Department of Medicine, Division of Hematology and Medical Oncology
University of Vermont Cancer Center
University of Vermont Office of Clinical Trials
Area(s) of expertise
My research focus is the intersection of thrombosis and cancer. I am the co-leader of a large cohort study of patients with advanced cancers who receive education, risk stratification and where applicable thromboprophylaxis at the UVMMC. Our team reports on multiple short and long term outcomes in this population as well as implementation research of this model in community oncology settings. I am also investigating the impact of a novel medical treatment for moderate to severe hot flashes in men receiving androgen deprivation therapy for prostate cancer.
These include clinical research around adjuvant treatment options for patients with esophageal and stomach cancers, supportive care for patients undergoing abdominal radiation therapy including novel combinations of antiemetics in this setting (AVERT trial: NCT00970905), and the protective impact of lipid lowering agents called statins on the risk of venous blood clots in patients with advanced cancer. I also participate in many national cooperative group trials covering the cancer sites listed above.
Dr. Ades' Recent Publications
1. Stout NL, Nikcevich D, Henderson TO, Steen P, Weiss M, Ades S, Mlodozyniec T, Koffarnus A, Barnick B, Paskett ED; Improving Rural Clinical Trial Enrollment: Recommendations From the Rural Health Working Group of the Alliance Clinical Trials Network. Clin Oncol. 2024 May 10;42(14):1722-1725. PMID 38412385
2. Perrapato SD, Farina NH, Berg AN, Wallace HJ, Ades S, Ahern TP, Stein JL, Stein GS, Lian JB. A MicroRNA Approach to Evaluating Elevated Prostate Cancer Risk in Cancer-Free Men. Rev Eukaryot Gene Expr. 2024;34(6):61-69. PMID: 38912963
3. Ades S, Resnick Y, Barker J, Martin K, Thomas R, Libby K, Winters J, Holmes C. Venous Thromboembolism prevention program implementation in a community oncology practice: A Cohort Study. Lancet Reg Health Am. 2024 Aug 29:38:100866. PMID: 39280881
4. Powles T, Catto JWF, Galsky, Al-Ahmadie H, Meeks JJ, Nishiyama H, Vu TQ, for the NIAGARA Investigators. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N Engl J Med 2024;391:1773-1786. PMID: 39282910
5. Ades S, Holmes C. Venous thromboembolism (VTE) prevention program implementation in a community oncology practice: author response to Yang et al. Lancet Reg Health Am 2025 Jan 2:42:100980. PMID 39850512
BIO
Dr. Steven Ades is a medical oncologist at the University of Vermont Medical Center and Professor of Medicine at Larner College of Medicine at the University of Vermont in Burlington, VT
Dr. Ades' postdoctoral training
2000-2002 Research Fellow, Tufts University School of Medicine, Boston, MA
1999-2002 Hematology/Oncology Fellowship, Tufts University, Boston MA
1996-1999 Queens University postgraduate education in Internal Medicine (Kingston General & Hotel Dieu Hospitals, Kingston, Ontario)
Publications
Bio
Dr. Steven Ades is a medical oncologist at the University of Vermont Medical Center and Professor of Medicine at Larner College of Medicine at the University of Vermont in Burlington, VT
Dr. Ades' postdoctoral training
2000-2002 Research Fellow, Tufts University School of Medicine, Boston, MA
1999-2002 Hematology/Oncology Fellowship, Tufts University, Boston MA
1996-1999 Queens University postgraduate education in Internal Medicine (Kingston General & Hotel Dieu Hospitals, Kingston, Ontario)